Sensus Healthcare (SRTS) announced it has entered into a strategic agreement with Radiology Oncology Systems to serve as the company’s primary distribution partner for the U.S. radiation oncology market. Under the terms of the agreement, ROS will be responsible for selling Sensus’s superficial radiotherapy systems, including the SRT-100 and the SRT-100 Vision, to hospital-based radiation oncology departments and freestanding oncology centers nationwide.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS:
- Sensus Healthcare Elects New Director at Annual Meeting
- Sensus Healthcare price target lowered to $10 from $14 at Maxim
- Sensus Healthcare: Strong Q1 Performance and Strategic Shifts Justify Buy Rating
- Sensus Healthcare’s Earnings Call: Mixed Outlook with Growth Potential
- Sensus Healthcare: Overcoming Challenges with Strategic Growth and Clinical Success